Mats Lundgren | CSO
Abera Bioscience AB

Dr. Mats Lundgren is a leading authority in vaccine discovery and development, with over 30 years of experience in the biopharmaceutical industry. His diverse background encompasses a wide range of roles, from scientist to vice president, equipping him with a thorough understanding of the scientific, strategic, and operational facets of vaccine and biopharmaceutical R&D.
Mats earned his PhD in Immunology from the prestigious Karolinska Institute, where he conducted research on antibody responses. He further refined his expertise during post-doctoral training at the Imperial College School of Medicine in London. Over the course of his career, he has held significant positions at Pharmacia, AstraZeneca, and various smaller biotech companies. Before joining Abera, he served as the Applications Director at Cytiva (formerly GE Healthcare), where he collaborated with vaccine and biopharma companies worldwide to enhance the development and production of new vaccines and therapies.
As Chief Scientific Officer at Abera, Mats leads the charge in vaccine innovation. He is currently focused on developing new vaccine candidates based on Abera's proprietary Outer Membrane Vesicle (OMV) platform for mucosal vaccination. This state-of-the-art technology has tremendous potential to improve vaccine efficacy and accessibility, particularly in the battle against infectious diseases.